Bicalutamide: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | ||
<scene name='54/543362/Bicalutamide_in_ar/3'>R-Bicalutamide</scene>, marketed as Casodex ref name="ARA prostate">PMID: 24639562</ref><ref name="nonsteroidal" />, is one of the most stable and tolerated ARA used in the treatment of prostate cancer <ref name="ARA prostate" /><ref name="bicalutamide" /><ref name="AAWS">PMID: 28971898</ref>, belonging to the first generation of antiandrogens developed <ref name="ARA prostate" /><ref name="MoA">PMID: 35245614</ref>. | <scene name='54/543362/Bicalutamide_in_ar/3'>R-Bicalutamide</scene>, marketed as Casodex <ref name="ARA prostate">PMID: 24639562</ref><ref name="nonsteroidal" />, is one of the most stable and tolerated ARA used in the treatment of prostate cancer <ref name="ARA prostate" /><ref name="bicalutamide" /><ref name="AAWS">PMID: 28971898</ref>, belonging to the first generation of antiandrogens developed <ref name="ARA prostate" /><ref name="MoA">PMID: 35245614</ref>. | ||
It is a competitive antagonist <ref name="Bicalutamide functions" /><ref name="MoA" /><ref name="AAWS" /> which binds to the LBD producing a transcriptionally inactive AR <ref name="Bicalutamide functions" />. However, it seems that the long-term use of these drugs and other first generation antiandrogens lead to withdrawal syndrome in prostate cancer resistant to castration patients <ref name="ARA prostate" /><ref name="nonsteroidal" />. In many cases, associated AR mutations, like W741L, can switch the mechanism of action of the drug from antagonist to agonist or partial agonist <ref name="ARA prostate" /><ref name="bicalutamide" /><ref name="nonsteroidal" /><ref name="Unexpected" /><ref name="MoA" />. | It is a competitive antagonist <ref name="Bicalutamide functions" /><ref name="MoA" /><ref name="AAWS" /> which binds to the LBD producing a transcriptionally inactive AR <ref name="Bicalutamide functions" />. However, it seems that the long-term use of these drugs and other first generation antiandrogens lead to withdrawal syndrome in prostate cancer resistant to castration patients <ref name="ARA prostate" /><ref name="nonsteroidal" />. In many cases, associated AR mutations, like W741L, can switch the mechanism of action of the drug from antagonist to agonist or partial agonist <ref name="ARA prostate" /><ref name="bicalutamide" /><ref name="nonsteroidal" /><ref name="Unexpected" /><ref name="MoA" />. | ||
Revision as of 16:43, 7 January 2024
, marketed as Casodex [1][2], is one of the most stable and tolerated ARA used in the treatment of prostate cancer [1][3][4], belonging to the first generation of antiandrogens developed [1][5]. It is a competitive antagonist [6][5][4] which binds to the LBD producing a transcriptionally inactive AR [6]. However, it seems that the long-term use of these drugs and other first generation antiandrogens lead to withdrawal syndrome in prostate cancer resistant to castration patients [1][2]. In many cases, associated AR mutations, like W741L, can switch the mechanism of action of the drug from antagonist to agonist or partial agonist [1][3][2][7][5]. Although bicalutamide has been patented since 1982 and approved to be clinical used by the FDA since 1995 [3], its mechanism of action is still under debate. The X-ray structure of the wild-type AR bound to an antagonist is not yet solved [5]. Changes in the conformation of the receptor, due to association with antagonists, have been hypothesized to be similar to those produced in the steroid receptor family [1][5]. When an agonist or a ligand binds to the LBD, it seems to induce a conformation of the steroid receptor which makes H12 closes off the pocket of LBD allowing the binding of cofactors. That permits the steroid receptor function allowing the DNA transcription [1]. Although, when an antagonist is bound, H12 seems to be more separated from the LBD, disabling the binding of coactivators [1] and the migration of the nuclear receptor into the nucleus [5]. Nonetheless, the AR has some structural singularities that may not let this change of conformation. One of the most important changes is the additional C-terminal region in H12 anchored to the receptor by the formation of a ß-sheet, limiting its movement [1][5]. Due to this structural difference, in silico approaches have suggested that the antiandrogen effect of bicalutamide may be produced by the instability of the homodimer [5]. That may lend to the dissociation of the homodimer preventing the transcriptional activity of the AR and explaining the mechanism of action of this drug [5]. In addition, in silico analysis have shown that the W741L mutation leads to a more stable bicalutamide-AR homodimer, which may provide some insight into the withdrawal syndrome observed in bicalutamide treatment [5]. For future research, it will be useful to understand the precise mechanism of action of antiandrogens currently used in the clinic, with the objective of developing new drugs which can escape from the antagonist-agonist switch seen in bicalutamide or flutamide. One example of this is apalutamide, a non-steroidal second generation antiandrogen [1][8], approved for use in non metastatic castration resistant prostate cancer patients by the FDA in 2018 [8]. See also the SPARTAN study[9]. This new drug has promising uses but it is still associated with side effects like an increased level of falls in patients with the treatment vs placebo [10].
|
| ||||||||||
ReferencesReferences
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, Joniau S, Claessens F. Androgen receptor antagonists for prostate cancer therapy. Endocr Relat Cancer. 2014 Aug;21(4):T105-18. doi: 10.1530/ERC-13-0545. Epub 2014 , Mar 17. PMID:24639562 doi:http://dx.doi.org/10.1530/ERC-13-0545
- ↑ 2.0 2.1 2.2 Cite error: Invalid
<ref>tag; no text was provided for refs namednonsteroidal - ↑ 3.0 3.1 3.2 Cite error: Invalid
<ref>tag; no text was provided for refs namedbicalutamide - ↑ 4.0 4.1 Leone G, Tucci M, Buttigliero C, Zichi C, Pignataro D, Bironzo P, Vignani F, Scagliotti GV, Di Maio M. Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. Endocr Relat Cancer. 2018 Jan;25(1):R1-R9. doi: 10.1530/ERC-17-0355. Epub 2017 , Sep 28. PMID:28971898 doi:http://dx.doi.org/10.1530/ERC-17-0355
- ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 Cavaliere F, Cozzini P. An insight about the mechanism of action (MoA) of R-bicalutamide on the androgen receptor homodimer using molecular dynamic. Toxicol Appl Pharmacol. 2022 Apr 1;440:115953. doi: 10.1016/j.taap.2022.115953. , Epub 2022 Mar 1. PMID:35245614 doi:http://dx.doi.org/10.1016/j.taap.2022.115953
- ↑ 6.0 6.1 Cite error: Invalid
<ref>tag; no text was provided for refs namedBicalutamide functions - ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedUnexpected - ↑ 8.0 8.1 Cite error: Invalid
<ref>tag; no text was provided for refs namedRole of AR - ↑ Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub , 2018 Feb 8. PMID:29420164 doi:http://dx.doi.org/10.1056/NEJMoa1715546
- ↑ Pollock Y, Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik B, Olmos D, Lee JY, Uemura H, Bhaumik A, Londhe A, Rooney B, Brookman-May SD, De Porre P, Mundle SD, Small EJ. Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide. Prostate Cancer Prostatic Dis. 2022 Oct 8. doi: 10.1038/s41391-022-00592-9. PMID:36209239 doi:http://dx.doi.org/10.1038/s41391-022-00592-9